The Pediatric infectious disease journal
-
Pediatr. Infect. Dis. J. · Feb 2003
Incidence and clinical features of hospitalization because of respiratory syncytial virus lower respiratory illness among children less than two years of age in a rural Asian setting.
Lower respiratory illness is the leading cause of child death in the developing world. Despite this few reports on respiratory syncytial virus (RSV) lower respiratory illness disease burden exist from rural areas of the developing world, and none exist for Indonesia. ⋯ Lombok has a large burden of severe childhood RSV lower respiratory illness, and death occurs frequently. Novel RSV vaccines thus could have a substantial positive impact on lower respiratory illness morbidity and mortality.
-
Pediatr. Infect. Dis. J. · Feb 2003
Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
In 1998 the Food and Drug Administration approved palivizumab (Synagis) for the prevention of severe lower respiratory tract infection secondary to respiratory syncytial virus (RSV) in pediatric patients at high risk for developing disease that required hospitalization. In the immediate aftermath of that approval, two retrospective reviews were conducted on 4669 medical records of patients who received at least 1 dose of palivizumab during the 1998 to 1999 and 1999 to 2000 RSV seasons, respectively. These analyses captured data on rates of RSV hospitalization, length of hospital stay, intensive care unit admission and compliance with palivizumab administration. Two prospective US multicenter registry trials followed, during the RSV seasons of 2000 to 2001 and 2001 to 2002. The registries characterized the demographics and outcomes of a total of 7207 high risk infants and children who received prophylaxis for RSV, the risk factors for RSV hospitalization and the patterns and scope of palivizumab usage across 63 and 116 US health care sites, respectively. 1998 TO 1999 PALIVIZUMAB FIRST SEASON OF GENERAL USE: Nine US study sites engaged in a retrospective chart review of infants and children with a gestational age of < or =35 weeks and a chronologic age of <2 years at the time of their first palivizumab injection and who had received at least one dose between September 1998 and May 1999. Of the 1839 prophylaxed children with evaluable data, only 42 (2.3%) were hospitalized with confirmed RSV disease. Of those admitted with confirmed gestational ages, all were premature; the majority were either < 28 weeks gestational age (WGA; 43%) or between 28 and 32 WGA (34%). 1999 TO 2000 PALIVIZUMAB SECOND SEASON OF GENERAL USE: During the 1999 to 2000 RSV season, 12 hospitals and university medical centers, representing a cross-section of US health care facilities, contributed to the second Palivizumab Study Group. The sites collected retrospective data from the charts of 2830 children, all of whom had received at least 1 injection of palivizumab between September 1999 and May 2000. Analysis of 2830 medical records revealed an admission rate of 2.4% (68 of 2830) for confirmed RSV infection, consistent with the overall hospitalization rate of 2.3% from the previous season. ⋯ 2001 to 2002: Between June 1, 2001 and May 15, 2002, 116 health care centers across the US enrolled 5091 infants in the second prospective Palivizumab Outcomes Registry. As its primary outcome the study measured the occurrence of RSV hospitalization with secondary variables of risk factors for RSV bronchiolitis and compliance with the projected number of palivizumab injections based on month of initial dose. Forty-nine percent (n = 2,501) of the infants were born between 32 and 35 weeks gestational age, 40% (n = 2020) were born at a gestational age of <32 weeks and 11% (n = 570) were born at >35 weeks gestational age. Nineteen percent (n = 964) of these children were deemed at sufficient risk to warrant palivizumab prophylaxis for a second season. Seventy-six of 5084 enrolled subjects experienced a total of 78 RSV-related hospital admissions, for an overall hospitalization rate of 1.5%. Four years of retrospective and prospective data on the use of palivizumab in clinical practice has accumulated a wealth of "real life" information on the clinical effectiveness of RSV immunoprophylaxis in a large cohort of high risk infants from geographically diverse pediatric offices and clinics throughout the United States.
-
Pediatr. Infect. Dis. J. · Feb 2003
Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
Among industrialized nations, the rate of rehospitalization in the United States for respiratory syncytial virus (RSV) is approximately 30 per 1000, exceptions being noted for American Indians and Alaskan natives, two ethnic groups who tend toward higher rates of RSV hospitalization. In distinction Japan reports an admission rate of 60 per 1000 for RSV disease. Yet Japan ranks considerably lower than many of its western counterparts in premature births. ⋯ Of those hospitalized during the 2 years of the study, 18 and 25%, respectively, were admitted to the intensive care unit. With the exception of higher rates of family allergy, multiple deliveries and a lower rate of neonatal morbidity, prognostic variables for high risk of hospital admission in the year 2000 compared with those of the 1999 sample. Findings from this comprehensive, prospective study served as the basis for the development of standards for the prevention of respiratory syncytial virus infection by the Spanish Society of Neonatology.
-
Pediatr. Infect. Dis. J. · Jan 2003
A wider role for congenital cytomegalovirus infection in sensorineural hearing loss.
Diagnostic problems in identifying congenital infection cases in infancy have thus far impaired the assessment of the role of congenital cytomegalovirus (CMV) infection in the etiology of sensorineural hearing loss (SNHL). ⋯ The results suggest that congenital CMV infection has a more relevant role in the etiology of SNHL than previously reported. The data obtained in both groups suggest that 20 to 30% of all deafness cases are caused by CMV. The percent of congenital CMV cases alone appears to account for all the cases previously attributed to all congenital infections. More than 40% of deafness cases with an unknown cause, needing rehabilitation, are caused by congenital CMV.